Skip to main content
. 2023 Sep 1;26(5):266–276. doi: 10.5223/pghn.2023.26.5.266

Table 2. HMO profiles by secretor–Lewis status.

HMO profiles (mg/L) Secretor status Lewis status Secretor–Lewis status
Secretor positive Weak secretor Lewis positive Lewis negative Secretor+newis+ Secretor+newis–
2’FL 2,292 (809–4,891)* 1,900 (49–2,670)* 2,150 (64–3,284) 1,969 (65–5,643) 2,150 (64–3,284) 1,969 (85–5,643)
LNFP I 591 (169–1,503) 394 (59–977) 490 (150–1,398) 340 (35–994) 490 (150–1,398) 341 (35–994)
LNT 106 (50–185) 109 (65–215) 111 (65–215) 104 (25–160) 111 (65–215) 104 (25–160)
LNnT 76 (36–119) 65 (38–102) 76 (38–118) 63 (29–87) 76 (38–118) 63 (29–87)
3’SL 188 (132–261) 188 (142–225) 190 (140–249) 177 (58–209) 190 (140–249) 177 (58–209)
6’SL 185 (132–260) 188 (142–223) 188 (139–246) 178 (56–208) 188 (139–246) 178 (56–208)

Values are presented as median (interquartile range).

HMO: human milk oligosaccharides, 2’FL: 2’-fucosyllactose, LNFP I: lacto-N-fucopentaose I, LNT: lacto-N-tetraose, LNnT: lacto-N-neotetraose, 3’SL: 3’-sialyllactose, 6’SL: 6’-sialyllactose.

*p-value<0.05.

Mann-Whitney test.

Kruskal-Wallis test.